Welcome to our dedicated page for Recursion Pharmaceuticals news (Ticker: RXRX), a resource for investors and traders seeking the latest updates and insights on Recursion Pharmaceuticals stock.
Recursion Pharmaceuticals, Inc. develops investigational medicines as a clinical-stage TechBio company using the Recursion OS, an AI-native drug discovery and development platform that integrates biology, chemistry, automation, data science and clinical development. Company updates center on wholly owned and partnered programs in oncology, rare disease, neuroscience, immunology and other therapeutic areas.
Recurring announcements cover clinical and preclinical pipeline progress, financial results, platform infrastructure, automated laboratory operations, collaborations and partner milestones. Recursion also reports governance and leadership changes, investor-conference participation and updates tied to named programs such as REC-1245, REC-4881 and REC-4539 when those programs advance through development.
Recursion (RXRX), a clinical stage TechBio company, has scheduled the release of its first quarter 2025 financial results on Monday, May 5, 2025, before market open. The company will host a live (L)earnings call at 8:00 am ET / 6:00 am MT / 1:00 pm GMT on the same day.
The earnings call will be broadcast live across multiple social media platforms, including X (formerly Twitter), LinkedIn, and YouTube. Stakeholders, including investors and analysts, can submit their questions through a dedicated online form.
Recursion (NASDAQ: RXRX) will present preliminary clinical data from its Phase 1b/2 TUPELO trial of REC-4881 for familial adenomatous polyposis (FAP) at Digestive Disease Week 2025. The presentation will take place on May 4, 2025, in San Diego.
Key preliminary findings as of February 7, 2025, show:
- 13 patients received 4 mg of REC-4881 daily
- 84.6% experienced at least one treatment-related adverse event
- Most common side effect was rash/dermatitis acneiform (Grade 1 or 2)
- 5 efficacy-evaluable patients showed >30% median reduction in total polyp burden after 12 weeks
REC-4881, identified through Recursion's AI-powered platform, has received Fast Track and Orphan Drug designations from the FDA and European Commission. FAP affects approximately 50,000 people across the US and major European countries, with no current FDA-approved therapies available.
Recursion (NASDAQ: RXRX) has partnered with HealthVerity to enhance its clinical trial capabilities through real-world data integration. The collaboration will give Recursion access to de-identified data covering over 340M lives in the US, which will be integrated into their Recursion OS platform.
This strategic partnership aims to improve clinical trial design, patient population insights, and trial feasibility assessments. Recursion will leverage HealthVerity's comprehensive healthcare data ecosystem to enhance their AI-driven approach, predict patient responses, and optimize study designs while ensuring regulatory compliance.
The integration of HealthVerity's real-world data into Recursion's platforms is expected to streamline clinical development, reduce costs, and accelerate the development of novel therapeutics while maintaining HIPAA compliance and patient privacy standards.
Recursion (NASDAQ: RXRX) and Enamine have announced a collaboration to create AI-enabled targeted compound libraries for drug discovery. The partnership combines Recursion's AI/ML platform (Recursion OS) with Enamine's REAL Space, the world's largest make-on-demand small molecule collection.
The collaboration has resulted in 10 enriched screening libraries comprising over 15,000 newly synthesized compounds, designed to accelerate drug discovery against 100 key clinical targets in challenging biological areas. By leveraging Recursion's AI technology to predict small molecule compatibility with protein targets, the partnership enables the creation of focused libraries that outperform traditional high-throughput screening collections.
As part of the research collaboration, Recursion gained access to tens of thousands of compounds for its internal discovery needs, while helping develop libraries of broad commercial interest. The curated libraries are now available through Enamine's website for customer hit-finding campaigns.
Recursion (RXRX) has initiated dosing in the Phase 1 EXCELERIZE clinical study of REC-3565, a selective MALT1 inhibitor designed for treating relapsed or refractory B-cell lymphomas. The compound, developed using Recursion's AI-powered platform, showed promising preclinical results with durable tumor regressions both as monotherapy and combined with BTK inhibitors.
The study consists of two parts: Part A will evaluate monotherapy dosing, while Part B will assess combination regimens. REC-3565's allosteric design aims to enhance potency and selectivity while potentially reducing liver toxicity risks associated with UGT1A1 inhibition, a common side effect in other MALT1 inhibitors.
Notably, the development timeline was accelerated, with the lead candidate delivered in just 15 months using the Recursion OS platform, which combines physics-based modeling with molecular dynamics and hotspot analysis.
Recursion (RXRX), a clinical stage TechBio company focused on drug discovery, has announced its upcoming participation in the Needham 24th Annual Virtual Healthcare Conference scheduled for April 7, 2025.
Investors and interested parties can access the conference webcasts through the events section of Recursion's Investor Relations website at ir.recursion.com.
Recursion (NASDAQ: RXRX) has strengthened its Board of Directors with two significant appointments effective March 15th. Dr. Namandjé Bumpus, former FDA Principal Deputy Commissioner until December 2024, brings extensive experience in regulatory science and AI integration. Elaine Sun, current COO and CFO at Mammoth Biosciences, contributes 30 years of life sciences and financial industry expertise.
Dr. Bumpus previously served as FDA's Chief Scientist and was instrumental in shaping the agency's strategic direction, particularly in AI regulatory science integration. She also held positions at Johns Hopkins University School of Medicine as an endowed professor and department chair.
Elaine Sun's experience includes leadership roles at Halozyme Therapeutics and SutroVax (now Vaxcyte), along with advisory roles in M&A and financing transactions exceeding $50 billion at Evercore Partners and Merrill Lynch. She currently serves on the boards of Dynavax Technologies and Asher Biotherapeutics.
Recursion (RXRX) reported its Q4 and FY2024 financial results, highlighting significant clinical and operational achievements. The company demonstrated promising safety and efficacy data for REC-617 in cancer treatment and REC-994 in cerebral cavernous malformations. Three new clinical studies were initiated across oncology, rare disease, and C. diff infection.
Key financial metrics for FY2024 include:
- Revenue: $58.8M (up from $44.6M in 2023)
- Cash position: $603.0M as of December 31, 2024
- Net loss: $463.7M (increased from $328.1M in 2023)
The company completed a strategic merger with Exscientia and delivered partnership milestones with Roche, Genentech, and Sanofi, generating $45M in cash inflows. Platform advancements include the launch of BioHive-2 supercomputer and development of new AI models. Cash runway is expected to extend into 2027.